Navigation Links
Infliximab scheduled treatment has proven to be an effective strategy in IBD patients
Date:10/25/2007

Crohn's disease (CD) and ulcerative colitis (UC) are chronic-relapsing diseases, the clinical courses of which are characterized by periods of remission and periods of acute flare up, determining clinical symptoms which have a strong impact on the quality of life for patients. For many years, corticosteroids have represented the cornerstone of therapy for induction of remission in Inflammatory Bowel Disease (IBD); however, the side-effects emerging with long-term use exceeded the clinical benefits. Recently, Infliximab (IFX) has become an alternative choice in the treatment strategies for CD and UC. Some safety issues are associated with IFX use, mostly related to the development of adverse events (e.g. opportunistic infections, autoimmune disorders and infusion reactions). Major concerns are related to the reactivation of latent tuberculosis and development of malignancy, even if there is no clear evidence the use of IFX increases the incidence of solid cancers. The research published on issue 39 of World Journal of Gastroenterology and led by Renato Caviglia at University Campus Biomedico in Italy aimed to retrospectively evaluate the safety and efficacy of long-term therapy with IFX, reviewing the medical charts of 41 IBD patients who received, after a loading dose of 3 IFX infusions, scheduled retreatment every 8 weeks as maintenance protocol.

Results of this retrospective study confirm current data on the efficacy of IFX in inducing a rapid clinical response in CD and UC, and support the finding, emerging from uncontrolled study data, of prolonged clinical efficacy in maintaining long-lasting remission beyond 1 year of treatment. The steroid-sparing effect of IFX was another important finding emerging from our study, which confirmed the efficacy of a scheduled treatment regimen in avoiding the well-known morbidity associated with long-term corticosteroid therapy. Interestingly, long-term IFX therapy in IBD has been demonstrated to potentially modify the course of the disease. Indeed, 9 out of the 29 CD and 4 out of the 9 UC patients, who discontinued IFX scheduled treatment, were still relapse-free after a median of 16 (range, 5-30) and 6.5 (range, 4-16) months since the last IFX infusion, respectively.

A note of caution is mandatory when considering the possible risk of malignancy associated with the use of anti-TNF-alpha therapy. Further studies on larger scales are needed to further clarify these important aspects.


'/>"/>

Contact: You-De Chang
y.d.chang@wjgnet.com
0086-108-538-1892
World Journal of Gastroenterology
Source:Eurekalert

Related medicine news :

1. Rescheduled: Aerial Mosquito Treatment for Philadelphia
2. First Keyhole Heart Valve Surgery Scheduled in Britain
3. Advances in Treatment of Cataracts
4. Recommendations for Treatment of Blood Pressue
5. Thyroid hormone treatment hastens recovery after cardiac surgery
6. Feeding channel created by malaria parasite - a new target for malaria treatments
7. Now umbilical cord helps in stroke treatment.
8. Now AIDS treatment comes dirt-cheap
9. Breast cancer treatment to be determined by gene test
10. Hemopurifier may revolutionise AIDS treatment
11. New drug helps boost cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... IL (PRWEB) , ... February 22, 2017 , ... South ... is proud to once again feature Heroes On The Water (HOW), a non-profit organization ... season’s all new episode has series host ‘Mike D’ traveling to Lake Denmark, New ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... chronic conditions reported skipping doses or not filling a prescription because they could ... rates of cost-related problems getting medications were 30-60%*. At the same ...
(Date:2/22/2017)... ... 2017 , ... Sideline Products participated in the World Horse Expo held in ... and his production crew. Tom Seay’s program “Best of America by Horseback” is ... Sidekicks will be featured on April 6, 2017. After the broadcast, the clip will ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... country today, as organizations, advocates, and individuals join together to increase recognition about ... to ultimately save lives. , “Today we mark a nationwide movement to raise ...
(Date:2/22/2017)... ... February 22, 2017 , ... Becker’s ... spine practices, is featuring Michigan neurosurgeon Jay Jagannathan, M.D., as a “Spine Surgeon ... small number of neurosurgeons in Michigan performing minimally invasive back surgery that often ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... Feb. 22, 2017 Summary Provides ... partnering deals and agreements entered into by the worlds ... http://www.reportlinker.com/p03605668-summary/view-report.html Description The Global Non-Small Cell Lung ... understanding and access to partnering deals and agreements entered ... - Trends in partnering deals - Top deals ...
(Date:2/22/2017)... , February 22, 2017 Arthroscopy Devices Market Report, published ... in 2015 and is projected to reach $5,334 million by 2022, growing at a ... of the total market in 2015. Continue Reading ... ... ...
(Date:2/22/2017)... MERIDEN, Conn. , Feb. 22, 2017   ... and maker of Flublok® Influenza Vaccine , announced ... The Partnership for Influenza Vaccine Introduction (PIVI) and the ... the devastating impacts of the flu.  The doses of ... of Mongolia for health care ...
Breaking Medicine Technology: